ME VS PHAT Stock Comparison

Performance

ME
10/100

ME returned -75.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

PHAT
10/100

PHAT returned -33.71% in the last 12 months. Based on SPY's performance of -13.30%, its performance is below average giving it a score of 10 of 100.

Technicals

ME
36/100

ME receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

PHAT
11/100

PHAT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

ME
10/100

ME has missed earnings 5 times in the last 20 quarters.

PHAT
10/100

PHAT has missed earnings 8 times in the last 20 quarters.

Profit

ME
10/100

Out of the last 14 quarters, ME has had 0 profitable quarters and has increased their profits year over year on 0 of them.

PHAT
10/100

Out of the last 20 quarters, PHAT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ME
45/100

ME has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

PHAT
49/100

PHAT has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Sentiment

ME

"Sentiment" not found for ME

PHAT
69/100

PHAT had a bullish sentiment score of 69.14% across Twitter and StockTwits over the last 12 months. It had an average of 5.51 posts, 3.36 comments, and 5.33 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

23andMe Holding Co. Class A Common Stock Summary

Nasdaq / ME

Healthcare

Medical - Diagnostics & Research

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Phathom Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / PHAT

Healthcare

Biotechnology

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Power up your portfolio